ERBB2 and non-small cell lung carcinoma: In this clinical trial, we aimed to evaluate the safety and efficacy of the dual HER2‐targeted therapy consisting of inetetamab and pyrotinib (240 mg, 320 mg) in advanced NSCLC patients with HER2 mutations.